Valuation: Agenus Inc.

Market Cap 353M 308M 291M 264M 495M 33.91B 497M 3.49B 1.35B 17.24B 1.33B 1.3B 55.48B P/E 2026 *
-196x
P/E 2027 * -17.2x
Enterprise Value 353M 308M 291M 264M 495M 33.91B 497M 3.49B 1.35B 17.24B 1.33B 1.3B 55.48B EV / Sales 2026 *
2.83x
EV / Sales 2027 * 3.06x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -
1 day+8.73%
1 week+13.11%
Current month+3.15%
1 month+4.25%
3 months+161.67%
6 months+108.78%
Current year+150.00%
1 week 6.81
Extreme 6.81
7.88
1 month 6.66
Extreme 6.66
8.52
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
25.4
5 years 1.38
Extreme 1.38
123.9
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Chief Executive Officer

1,971,500 4.4054%
5/8/26 Free

Director

50,000 0.1117%
5/8/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
+8.73%+13.11%+72.53%-68.60% 353M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -0.02%+4.70%+53.65%+97.03% 26.27B
Weighted average by Cap. -1.01%+1.89%+64.70%+129.93%

Financials

2026 *2027 *
Net sales 125M 109M 103M 93.46M 175M 11.99B 176M 1.23B 476M 6.1B 470M 459M 19.62B 115M 101M 95.02M 86.28M 162M 11.07B 162M 1.14B 439M 5.63B 434M 424M 18.11B
Net income 35.2M 30.69M 28.98M 26.32M 49.31M 3.38B 49.52M 347M 134M 1.72B 132M 129M 5.53B -26.1M -22.76M -21.49M -19.51M -36.56M -2.5B -36.71M -257M -99.34M -1.27B -98.04M -95.87M -4.1B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
18/09/26 USD 7.850 +8.73% 2,084,681
17/09/26 USD 7.220 +0.14% 765,417
16/09/26 USD 7.210 +0.70% 687,079
15/09/26 USD 7.160 +0.42% 779,518
14/09/26 USD 7.130 +2.74% 752,308
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.850USD
Average target price
26.33USD
Spread / Average Target
+235.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!